SP 1049C

Drug Profile

SP 1049C

Alternative Names: Doxorubicin SP1000 - Supratek Pharma; SP-1049C

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator Supratek Pharma
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Adenocarcinoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Jan 2011 No development reported - Phase-II for Adenocarcinoma in United Kingdom (IV)
  • 28 Nov 2007 US FDA, under a Special Protocol Assessment (SPA), approves the design of phase III study protocol of SP 1049C in metastatic adenocarcinoma of the upper GI
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top